(Q34800470)

4 August 2017

1 reference

title

Clinical trials for drugs against diabetic neuropathy: can we combine scientific needs with clinical practicalities? (English)

1 reference

4 August 2017

1 reference

Dan Ziegler

1

1 reference

4 August 2017

Dieter Luft

series ordinal

2

1 reference

4 August 2017

publication date

1 January 2002

1 reference

International Review of Neurobiology

4 August 2017

published in

1 reference

4 August 2017

volume

50

1 reference

4 August 2017

page(s)

431-463

1 reference

Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Diabetic polyneuropathy in controlled clinical trials: Consensus Report of the Peripheral Nerve Society

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Better reporting of randomised controlled trials: the CONSORT statement

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Statistics notes: Absence of evidence is not evidence of absence

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

The effect of 8 years of strict glycaemic control on peripheral nerve function in IDDM patients: the Oslo Study

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Some examples of regression towards the mean

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Surrogate endpoints: a basis for a rational approach

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Electrophysiological monitoring in clinical trials. Roche Neuropathy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Potential therapeutic approaches to the treatment or prevention of diabetic neuropathy: evidence from experimental studies

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Metabolic and vascular factors in the pathogenesis of diabetic neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Effects of alpha-lipoic acid on neurovascular function in diabetic rats: interaction with essential fatty acids

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

A method for assessing the quality of a randomized control trial

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

The number needed to treat: a clinically useful measure of treatment effect

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Showing neuropathy is related to increased mortality in diabetic patients - a survival analysis using an accelerated failure time model

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Number-needed-to-treat and placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Vibratory and cooling detection thresholds compared with other tests in diagnosing and staging diabetic neuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Meaningful degrees of prevention or improvement of nerve conduction in controlled clinical trials of diabetic neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Concept of true and perceived placebo effects

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Surrogate end points in clinical trials: are we being misled?

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Risk factors for mortality in Type II (non-insulin-dependent) diabetes: evidence of a role for neuropathy and a protective effect of HLA-DR4

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Biological activity of C-peptide on the skin microcirculation in patients with insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II).

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Simplified diagnostic criteria for diabetic distal polyneuropathy. Preliminary data of a multicentre study in the Campania region. S.I.M.S.D.N. Group

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Patient compliance and the conduct and interpretation of therapeutic trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Essential fatty acids in the management of impaired nerve function in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

A lipoic acid-gamma linolenic acid conjugate is effective against multiple indices of experimental diabetic neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Treatment of diabetic neuropathy with gamma-linolenic acid. The gamma-Linolenic Acid Multicenter Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Protein kinase C activation and the development of diabetic complications

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Reduced intraindividual variability of repeated cardiovascular reflex tests: an additional marker of autonomic neuropathy in insulin-dependent (type I) diabetes mellitus?

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Meta-analysis in clinical research

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

An assessment of clinically useful measures of the consequences of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

The tuning fork revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Interpretation of clinical trials for the treatment of diabetic neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Can diabetic neuropathy be prevented by angiotensin-converting enzyme inhibitors?

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Measuring diabetic neuropathy. Assessment and comparison of clinical examination and quantitative sensory testing

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Statistical power, sample size, and their reporting in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Impairment, disability, or handicap in peripheral neuropathy: analysis of the use of outcome measures in clinical trials in patients with peripheral neuropathies

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian Study Group. The St. Vincent Declaration

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

The efficacy of tolrestat in the treatment of diabetic peripheral neuropathy. A meta-analysis of individual patient data

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Quantitative sensory testing: a consensus report from the Peripheral Neuropathy Association

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Gangliosides and Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Independent effects of peripheral nerve dysfunction on lower-extremity physical function in old age: the Women's Health and Aging Study

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

The continuing unethical use of placebo controls

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Can overall results of clinical trials be applied to all patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Incidence of distal symmetric (sensory) neuropathy in NIDDM. The San Luis Valley Diabetes Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Reversal of experimental diabetic neuropathy by VEGF gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Design of controlled clinical trials for diabetic polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Improvement in chronic ischemic neuropathy after intramuscular phVEGF165 gene transfer in patients with critical limb ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Surrogates, semantics, and sensible public policy

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

In-vitro assessment of a hypersensitivity syndrome associated with sorbinil

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Measuring vibration sensations with graduated tuning fork. Simple and reliable means to detect diabetic patients at risk of neuropathic foot ulceration

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Diabetic neuropathy. Human and experimental

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Can meta-analyses be trusted?

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Lipo-PGE1, a new lipid-encapsulated preparation of prostaglandin E1: placebo-and prostaglandin E1-controlled multicenter trials in patients with diabetic neuropathy and leg ulcers

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

The importance of placebo effects in pain treatment and research

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Reversal of defective nerve conduction with vitamin E supplementation in type 2 diabetes: a preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Reproducibility of parameters for assessment of diabetic neuropathy. The French Group for Research and Study of Diabetic Neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Can VEGF reverse diabetic neuropathy in human subjects?

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Variance of sensory threshold measurements: discrimination of feigners from trustworthy performers

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

Variability in vibration perception threshold among sites: a potential source of error in biothesiometry

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950085-4

7 January 2021

10.1016/S0074-7742(02)50085-4

Identifiers

DOI

1 reference

4 August 2017

1 reference